A population-based study of the use of radium 223 in metastatic castration-resistant prostate cancer: Factors associated with treatment completion

摘要

Introduction Radium 223 (Ra223) given for six cycles has proven efficacy in clinical trials, but its population-level generalizability has not been well-described. The objectives of this study were to describe population-based Ra223 use in the abiraterone and enzalutamide era and identify factors associated with completion. Go to: Methods All Ra223 patients at the British Columbia Cancer Agency between September 2013 and February 2016 were identified. Patients who completed 30% from baseline (R30%), and survival, to identify factors associated with therapy completion. Go to: Results Ninety-one patients were identified; 48 (52.7%) completed >5 cycles. Median overall survival (mOS) was 10.7 months, PSA and ALP R30% were 21% and 52%, respectively. Completion of 118. Go to: Conclusions Compared to clinical trials, patients in a population-based setting had more lines of therapy and shorter survival. Lower ALP and higher hemoglobin were associated with completion of >5 cycles, longer mOS, and greater incidence of PSA and ALP response.